ווטריינט 400 מג Izraēla - ivrits - Ministry of Health

ווטריינט 400 מג

novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 400 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

טיויקיי 10 מג Izraēla - ivrits - Ministry of Health

טיויקיי 10 מג

glaxo smith kline (israel) ltd - dolutegravir as sodium - טבליות מצופות פילם - dolutegravir as sodium 10 mg - dolutegravir

טיויקיי 25 מג Izraēla - ivrits - Ministry of Health

טיויקיי 25 מג

glaxo smith kline (israel) ltd - dolutegravir as sodium - טבליות מצופות פילם - dolutegravir as sodium 25 mg - dolutegravir

טיויקיי 50 מג Izraēla - ivrits - Ministry of Health

טיויקיי 50 מג

glaxo smith kline (israel) ltd - dolutegravir as sodium - טבליות מצופות פילם - dolutegravir as sodium 50 mg - dolutegravir

פירון 267 Izraēla - ivrits - Ministry of Health

פירון 267

unipharm ltd, israel - pirfenidone - טבליה - pirfenidone 267 mg - pirfenidone

פירון 801 Izraēla - ivrits - Ministry of Health

פירון 801

unipharm ltd, israel - pirfenidone - טבליה - pirfenidone 801 mg - pirfenidone

פרגמין 25000 יבל מל Izraēla - ivrits - Ministry of Health

פרגמין 25000 יבל מל

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 5000 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism.unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

אלפו-קל XL Izraēla - ivrits - Ministry of Health

אלפו-קל xl

padagis israel agencies ltd, israel - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason.

פרינג'קט Izraēla - ivrits - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial - ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. the diagnosis must be based on laboratory tests.

בינוקריט 1000 יחבל 0.5 מל Izraēla - ivrits - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob